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Abstract. Antiretroviral administration affects weight gain and inflammation in HIV 
patients. The purpose of the study was to assess the relationship of body mass index with 
inflamation parameters in HIV patients who ARV therapy. In 40 HIV patients (stage III-IV)   
treated with ARV (FDC 87%, Durival Efaviren 7.5%, Tenofovir, Huviral, Aluvia 2.5%, and 
Tenofovir, Huviral, Neviral 2.5%) conducted observational analytics with crosssectional 
design. CD4 examination was carried out flowcytometrically, BMI measured by formula 
weight (kg) divided by height squared (m2), waist circumference (WC) measured by ribbon 
between costae arcus and anterior superior iliac spine, albumin measurement with Brom 
Cresol Green (BCG) method. There is a significant correlation between BMI with WC and 
CD4 (r=0.61, p<0.001 and r=0.38, p<0.001, respectively). There is no correlation between 
BMI and duration of ARV treatment, albumin and leptin. ARV treatment in HIV patients 
will affect weight and inflammatory markers. 
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Abstrak. Pemberian antiretrovirus akan mempengaruhi berat badan dan inflamasi pada 
pasien HIV. Tujuan penelitian menilai hubungan indeks masa tubuh dengan parameter 
inflasi pada pasien HIV yang mendapatkan terapi ARV. Terhadap 40 penderita HIV (stadium 
III-IV) yang diterapi ARV  (FDC 87%, Durival Efaviren 7,5%, Tenofovir, Huviral, Aluvia 
2,5%, dan Tenofovir, Huviral, Neviral 2,5%) dilakukan studi analitik observasional dengan 
desain crosssectional. Pemeriksaan CD4 dilakukan menggunakan metode flowcytometry, 
BMI diukur dengan bobot formula (kg) dibagi dengan tinggi badan kuadrat (m2), lingkar 
pinggang (WC) diukur dengan pita antara arcus costae dan SIAS, pengukuran albumin 
dengan metode Brom Cresol Green (BCG). Terdapat korelasi yang signifikan antara BMI 
dengan WC dan CD4 (r=0.61, p<0.001 and r=0.38, p<0.001, secara berurutan). Tidak 
terdapat korelasi antara IMT dengan lama pengobatan, albumin dan leptin. Pengobatan 
ARV pada pasien HIV akan mempengaruhi berat badan dan penanda inflamasi. 
Kata Kunci: ARV, Berat Badan, CD4 
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1 Introduction 
An increasing prevalence of overweight and obesity has also been reported in people living with 
human immunodeficiency virus (PLWH), among whom initiation of antiretroviral therapy (ART) 
often leads to weight gain [1]. Although this weight gain may be a positive prognostic indicator 
in PLWH who are underweight at the time of ART initiation, [2] among those in normal or 
overweight categories, weight gain may increase the risk of cardiovascular and metabolic diseases 
[3]. Possible mechanisms for ART-associated weight gain include a return-to-health 
phenomenon, especially in those with advanced human immunodeficiency virus (HIV) disease, 
with weight returning to a pre-illness baseline. The mechanism underlying the return-to-health 
phenomenon is incompletely understood, but likely results from the alleviation of HIV-associated 
inflammation and accelerated catabolism [4]. Treatment of HIV may also hasten resolution of 
opportunistic infections and gastrointestinal (GI) dysfunction that could adversely affect appetite 
and nutrient. 
Specific ART regimens or drug classes have also been implicated in weight gain, with integrase 
strand transfer inhibitors (INSTIs) cited in 2 randomized studies [5] and several retrospective 
cohort studies [6]. Highly active antiretroviral therapy (HAART)-induced lipoatrophy, currently 
the most common form of lipoatrophy worldwide, is associated with hypoleptinemia, insulin 
resistance, and elevated triglycerides in the context of the HAART-induced metabolic syndrome 
(HAART-MS) [7]. 
Based on this, study will research how the relationship between body mass index and CD4 in HIV 
patients who get antiretroviral (ARV). 
2 Method 
The study was conducted on 40 HIV patients (stage III-IV), type ARV used is FDC 87%, Durival 
Efaviren 7.5%, Tenofovir, Huviral, Aluvia 2.5%, and Tenofovir, Huviral, Neviral 2.5%. This 
research is based on observational analytical studies with cross-sectional research design, and 
consecutive sampling of samples that meet inclusion and exclusion criteria. The inclusion criteria 
are men and women aged 18 to 60 years, HIV-diagnosed and on antiretroviral therapy for at least 
2 months, and adhere to drug consumption. The exclusion criteria are HIV patients with 
comorbidities (diabetes, cardiovascular disease, renal dysfunction, malignancy, and autoimmune 
disease), opportunistic infection, and hormonal dysregulation. CD4 examination is done 
flowcitometrically, BMI is measured by formula weight (kg) divided by height squared (m2), 
waist circumference (WC) measured by ribbon between arcus costae and SIAS, albumin 
measurement with Brom Cresol Green (BCG) method. 
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2.1 Statistical analysis 
A normality test of the data is performed, normal distributed in the form of mean with standard 
deviation, if not normal distributed prepared in the form with maximum-minimum. The statistical 
analysis used to assess the relationship of BMI with other anthropometric parameters is Pearson 
test if the variables are normally distributed and Spearman test if the distribution is abnormal.  
3 Result 
The basic parameters of the research subjects in Table 1. 
Table 1. Basic data of HIV patients 
Parameter Mean ± SD 
Age (year) 33.62 ± 7.61 
WC (cm) 76.17 ± 9.87 
BMI (kg/m2) 21.29 ± 3.46 
CD4 (cell/mm3) 330.55 ± 163.98 
ARV treat (month) 2.40 ± 2.34 
Albumin (gr/dL) 3.68 ± 0.82 
Leptin (ng/mL) 11.98 ± 8.32 
 
In table 2, There is a significant correlation between BMI and WC and CD4. 
Table 2. Correlation between BMI and inflammatory parameters 
Parameter R P 
Age (year) -0.01 0.469 
WC (cm) 0.61 0.001** 
CD4 (cell/mm3) 0.38 0.001** 
ARV treat (month) 0.10 0.270 
Albumin (gr/dL) 0.21 0.097 
Leptin (ng/mL) 0.18 1.32 
                      ** significance 
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4 Discussion 
The causes underlying the progressive rise in body weight among the HIV-infected population 
are likely a complex mix of interrelated and shifting lifestyle trends in society at large, HIV 
provider and patient conceptions of health and priorities for care, changes in guidelines for 
initiating ART, and the introduction of new ART agents, among other factors [8]. It is reasonable 
to assume that HIV patients are similarly affected by factors driving obesity in the general 
population, particularly as earlier treatment and effective ART preempt the cachexia common in 
advanced untreated disease [9].  
If individual agents contribute to weight gain aside from tolerability, the mechanisms by which 
they do so is not known. For treatment-naive PLWH, some of the association between weight 
gain and INSTI-containing regimens could be their faster virologic control compared to older 
regimens [10]. Another explanation for drug-specific effects on weight could be off-target 
biological interactions. One such example is the observed interaction between DTG and 
melanocortin 4 receptor (MC4R), a receptor involved in the regulation of caloric intake by 
modulating leptin signaling in the central nervous system [11]. This finding is intriguing as 
mutations in MC4R are associated with heritable obesity [12]. This potential mechanism requires 
further validation, and it remains unknown whether other INSTIs interact similarly. 
Evaluating the effect of ART drugs on weight gain is confounded by HIV disease factors such as 
return to health; some of these limitations may be avoided by studying weight changes in 
preexposure prophylaxis (PrEP) trials. In the Iniciativa Profilaxis Pre-Exposición study 
comparing TDF/FTC to placebo, the TDF/FTC arm gained less weight than placebo, suggesting 
that TDF/FTC may have a mild weight-suppressive effect [13]. In the DISCOVER trial of 
TDF/FTC vs TAF/FTC for PrEP, weight gain at week 48 was 1.1 kg in the TAF/FTC arm with 
no change in the TDF/FTC arm [14]. Finally, in a phase 2 placebo controlled trial of cabotegravir 
for PrEP, both arms ex- perienced about 1 kg of weight gain over 41 weeks, with no significant 
difference between arms [14]. Together these findings suggest that heathy participants taking TAF 
or an INSTI likely experience weight gain much like the general population, which contrasts with 
the weight-suppressive effect of TDF. 
In this studies, there is significant correlation between BMI and WC and CD4 (r=0.61, p<0.001 
and r=0.38, p<0.001, respectively), then the administration of ARVs in HIV patients will affect 
weight and inflammation marker.There are several limitations of this study. We have data of wide 
variation duration treatment ART. Our stuies did not evaluate other potential contributors to 
weight gain such as psychiatric comorbidities, concomitant medications, diet, physical activity, 
or smoking. In the included trials, newer third agents were generally coadministered with ART. 
Duration of treatment is an average of two months and  BMI status of normoweight-overweight 
patients. 
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5 Conclusion 
The administration of ARV in HIV patients will affect body weight  and inflammatory markers. 
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